% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Unkelbach:136905,
author = {J. Unkelbach and M. Bangert$^*$ and K. De Amorim Bernstein
and N. Andratschke and M. Guckenberger},
title = {{O}ptimization of combined proton-photon treatments.},
journal = {Radiotherapy and oncology},
volume = {128},
number = {1},
issn = {0167-8140},
address = {Amsterdam [u.a.]},
publisher = {Elsevier Science},
reportid = {DKFZ-2018-01343},
pages = {133 - 138},
year = {2018},
abstract = {Proton treatment slots are a limited resource. Therefore,
we consider combined proton-photon treatments in which most
fractions are delivered with photons and only a few with
protons. We demonstrate how both modalities can be combined
to optimally capitalize on the proton's ability to reduce
normal tissue dose.An optimal combined treatment must
account for fractionation effects. We therefore perform
simultaneous optimization of intensity-modulated proton
(IMPT) and photon (IMRT) plans based on their cumulative
biologically effective dose (BED). We demonstrate the method
for a sacral chordoma patient, in whom the gross tumor
volume (GTV) abuts bowel and rectum.In an optimal
combination, proton and photon fractions deliver similar
doses to bowel and rectum to protect these dose-limiting
normal tissues through fractionation. However, proton
fractions deliver, on average, higher doses to the GTV.
Thereby, the photon dose bath is reduced. An optimized
30-fraction treatment with 10 IMPT fractions achieved more
than $50\%$ of the integral dose reduction in the
gastrointestinal tract that is possible with 30 IMPT
fractions (compared to $33\%$ for a simple proton-photon
combination in which both modalities deliver the same target
dose).A limited number of proton fractions can best be used
if protons hypofractionate parts of the GTV while
maintaining near-uniform fractionation in dose-limiting
normal tissues.},
cin = {E040},
ddc = {610},
cid = {I:(DE-He78)E040-20160331},
pnm = {315 - Imaging and radiooncology (POF3-315)},
pid = {G:(DE-HGF)POF3-315},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:29370987},
doi = {10.1016/j.radonc.2017.12.031},
url = {https://inrepo02.dkfz.de/record/136905},
}